{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-018937","form_type":"8-K","ticker":"AUPH","cik":"0001600620","company_name":"Aurinia Pharmaceuticals Inc.","filed_at":"2022-07-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.320438+00:00","generated_at":"2026-06-24T14:06:58.666830+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Aurinia and CCO Max Colao mutually agree to separation effective July 22","bullets":["Max Colao, Chief Commercial Officer, will cease employment on July 22, 2022 by mutual agreement.","Severance includes 12 months base salary ($488,835) plus eligibility for performance bonus (target $244,418).","COBRA benefits for up to 12 months if elected.","No replacement named; separation agreement expected to mirror existing employment terms."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-018937","json":"https://secwatch.observer/filing/0001628280-22-018937.json","markdown":"https://secwatch.observer/filing/0001628280-22-018937.md","text":"https://secwatch.observer/filing/0001628280-22-018937.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600620/000162828022018937/0001628280-22-018937-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600620/000162828022018937/auph-20220715.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T14:06:58.666830+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4f36347d7e","claim":"Max Colao departed as Chief Commercial Officer at Aurinia Pharmaceuticals Inc..","evidence_excerpt":"On July 11, 2022, Aurinia Pharmaceuticals Inc. and Max Colao, our Chief Commercial Officer, mutually agreed that Mr. Colao would cease his employment with Aurinia, effective July 22, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828022018937/0001628280-22-018937-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"mutually agreed to cease employment"},{"label":"Role","value":"Chief Commercial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}